ES2055962T5 - Preparado farmaceutico de liberacion controlada. - Google Patents

Preparado farmaceutico de liberacion controlada.

Info

Publication number
ES2055962T5
ES2055962T5 ES91305834T ES91305834T ES2055962T5 ES 2055962 T5 ES2055962 T5 ES 2055962T5 ES 91305834 T ES91305834 T ES 91305834T ES 91305834 T ES91305834 T ES 91305834T ES 2055962 T5 ES2055962 T5 ES 2055962T5
Authority
ES
Spain
Prior art keywords
controlled release
pharmaceutical preparation
water
medicinal compound
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91305834T
Other languages
English (en)
Other versions
ES2055962T3 (es
Inventor
Kazuo Noda
Takashi Osawa
Masao Kobayashi
Shigeyuki Ishikawa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tanabe Pharma Corp
Original Assignee
Tanabe Seiyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26494375&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2055962(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tanabe Seiyaku Co Ltd filed Critical Tanabe Seiyaku Co Ltd
Publication of ES2055962T3 publication Critical patent/ES2055962T3/es
Application granted granted Critical
Publication of ES2055962T5 publication Critical patent/ES2055962T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Surgical Instruments (AREA)
  • Stringed Musical Instruments (AREA)
  • Pens And Brushes (AREA)

Abstract

SE PRESENTA UNA PREPARACION FARMACEUTICA DE LIBERACION CONTROLADA QUE COMPRENDE UN NUCLEO QUE CONTIENE UN COMPUESTO MEDICINAL Y UNA CAPA DE RECUBRIMIENTO QUE CONTIENE UNA SAL REPELENTE DEL AGUA Y UN POLIMERO ACRILICO INSOLUBLE EN AGUA Y LIGERAMENTE PERMEABLE A LA MISMA QUE TIENE UN GRUPO TRIMETIL AMONIOMETIL. DICHA PREPARACION LIBERA UN COMPUESTO MEDICINAL EN UNA FORMA DE DISOLUCION DE TIPO SIGMOIDE CON INDEPENDENCIA DEL PH DEL MEDIO DE DISOLUCION.
ES91305834T 1990-06-28 1991-06-27 Preparado farmaceutico de liberacion controlada. Expired - Lifetime ES2055962T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP17176290 1990-06-28
SG4995A SG4995G (en) 1990-06-28 1995-01-13 Controlled release pharmaceutical preparation

Publications (2)

Publication Number Publication Date
ES2055962T3 ES2055962T3 (es) 1994-09-01
ES2055962T5 true ES2055962T5 (es) 1997-09-16

Family

ID=26494375

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91305834T Expired - Lifetime ES2055962T5 (es) 1990-06-28 1991-06-27 Preparado farmaceutico de liberacion controlada.

Country Status (17)

Country Link
US (1) US5137733A (es)
EP (1) EP0463877B2 (es)
JP (1) JP2558396B2 (es)
KR (1) KR0133511B1 (es)
CN (1) CN1040061C (es)
AT (1) ATE106241T1 (es)
CA (1) CA2045358C (es)
DE (1) DE69102211T3 (es)
DK (1) DK0463877T3 (es)
ES (1) ES2055962T5 (es)
FI (1) FI103476B1 (es)
GR (1) GR3024471T3 (es)
HK (1) HK33895A (es)
HU (1) HU214590B (es)
IE (1) IE64629B1 (es)
IL (1) IL98611A (es)
SG (1) SG4995G (es)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5286493A (en) * 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US7070806B2 (en) 1992-01-27 2006-07-04 Purdue Pharma Lp Controlled release formulations coated with aqueous dispersions of acrylic polymers
CN1053808C (zh) * 1993-04-24 2000-06-28 章修纲 尼非地平控释剂型
JP2916978B2 (ja) * 1993-08-25 1999-07-05 エスエス製薬株式会社 放出開始制御型製剤
US5834024A (en) * 1995-01-05 1998-11-10 Fh Faulding & Co. Limited Controlled absorption diltiazem pharmaceutical formulation
US5567441A (en) * 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
US5922736A (en) * 1995-12-04 1999-07-13 Celegene Corporation Chronic, bolus administration of D-threo methylphenidate
US5837284A (en) * 1995-12-04 1998-11-17 Mehta; Atul M. Delivery of multiple doses of medications
US6486177B2 (en) * 1995-12-04 2002-11-26 Celgene Corporation Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US5830503A (en) * 1996-06-21 1998-11-03 Andrx Pharmaceuticals, Inc. Enteric coated diltiazem once-a-day formulation
US6962997B1 (en) * 1997-05-22 2005-11-08 Celgene Corporation Process and intermediates for resolving piperidyl acetamide steroisomers
CA2270975C (en) 1997-07-02 2003-04-01 Euro-Celtique, S.A. Stabilized sustained release tramadol formulations
US6303144B1 (en) 1998-02-10 2001-10-16 Welfide Corporation Preparations with controlled release
FR2778848B1 (fr) * 1998-05-20 2001-11-23 Prographarm Lab Forme pharmaceutique multiparticulaire a liberation programmee et pulsee et son procede de preparation
US6524620B2 (en) 1998-07-20 2003-02-25 Andrx Pharmaceuticals, Inc. Diltiazem controlled release formulation and method of manufacture
DE19845358A1 (de) * 1998-10-02 2000-04-06 Roehm Gmbh Überzogene Arzneiformen mit kontrollierter Wirkstoffabgabe
US20010055613A1 (en) 1998-10-21 2001-12-27 Beth A. Burnside Oral pulsed dose drug delivery system
US6270805B1 (en) 1998-11-06 2001-08-07 Andrx Pharmaceuticals, Inc. Two pellet controlled release formulation for water soluble drugs which contains an alkaline metal stearate
US6039979A (en) * 1999-01-13 2000-03-21 Laboratoires Prographarm Multiparticulate pharmaceutical form with programmed and pulsed release and process for its preparation
US6733789B1 (en) 1999-01-21 2004-05-11 Biovail Laboratories, Inc. Multiparticulate bisoprolol formulation
ES2267491T3 (es) * 1999-01-21 2007-03-16 Circ Pharma Research And Development Limited Formulacion de bisoprolol de multiples particulas.
GB9923436D0 (en) * 1999-10-04 1999-12-08 American Home Prod Pharmaceutical compositions
AU783685B2 (en) * 1999-12-23 2005-11-24 Pfizer Products Inc. Hydrogel-driven drug dosage form
EA006402B1 (ru) 1999-12-23 2005-12-29 Пфайзер Продактс Инк. Комбинация лекарства и целлюлозного полимера, повышающего концентрацию; способ введения лекарства и водный раствор (варианты)
US20040185099A1 (en) * 2000-01-20 2004-09-23 Biovail Laboratories, Inc. Multiparticulate bisoprolol formulation
US6635277B2 (en) 2000-04-12 2003-10-21 Wockhardt Limited Composition for pulsatile delivery of diltiazem and process of manufacture
US6984402B2 (en) 2000-10-03 2006-01-10 Elite Laboratories, Inc. Chrono delivery formulations and method of treating atrial fibrillation
US6620439B1 (en) * 2000-10-03 2003-09-16 Atul M. Mehta Chrono delivery formulations and method of use thereof
SE0100200D0 (sv) 2001-01-24 2001-01-24 Astrazeneca Ab New film coating
US7125561B2 (en) * 2001-05-22 2006-10-24 Euro-Celtique S.A. Compartmentalized dosage form
US9358214B2 (en) 2001-10-04 2016-06-07 Adare Pharmaceuticals, Inc. Timed, sustained release systems for propranolol
US20030091633A1 (en) * 2001-11-15 2003-05-15 John Kelly Methods and compositions for use of (S)-bisoprolol
US20030118652A1 (en) * 2001-11-15 2003-06-26 John Kelly Methods and compositions for use of (S)-bisoprolol
US20050025824A1 (en) * 2001-12-14 2005-02-03 Eurand Pharmaceuticals Ltd. Pulsatile release histamine H2 antagonist dosage form
US6663888B2 (en) 2001-12-14 2003-12-16 Eurand Pharmaceuticals Ltd. Pulsatile release histamine H2 antagonist dosage form
US8367111B2 (en) * 2002-12-31 2013-02-05 Aptalis Pharmatech, Inc. Extended release dosage forms of propranolol hydrochloride
JP4813179B2 (ja) * 2003-03-11 2011-11-09 生化学工業株式会社 光架橋多糖組成物およびその製造方法
CA2523158C (en) 2003-04-24 2010-11-16 Jagotec Ag Delayed release tablet with defined core geometry
FR2861990B1 (fr) * 2003-11-10 2006-02-10 Nouveaux Produits Pharma Comprimes faiblement doses a reseau de polymeres
US20050239830A1 (en) * 2004-04-26 2005-10-27 Vikram Khetani Methods of diminishing co-abuse potential
JP4722837B2 (ja) * 2004-05-07 2011-07-13 生化学工業株式会社 髄核充填剤
DE102004043863A1 (de) 2004-09-10 2006-03-16 Nitec Pharma Ag Tabletten mit orts- und zeitgesteuerter Wirkstofffreisetzung im Gastrointestinum
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
ES2409347T3 (es) 2004-10-21 2013-06-26 Aptalis Pharmatech, Inc. Composiciones farmacéuticas de sabor enmascarado con agentes porogénicos gastrosolubles
NZ555842A (en) * 2004-12-09 2010-10-29 Celgene Corp Treatment of various conditions of patients with Tourette syndrome, tics, or a family history thereof sing D-threo methylphenidate free from other isomers
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
US8846100B2 (en) * 2006-05-12 2014-09-30 Shire Llc Controlled dose drug delivery system
SG174026A1 (en) 2006-08-03 2011-09-29 Nitec Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid disease
JP2008024708A (ja) * 2007-08-20 2008-02-07 Euro-Celtique Sa アクリル系ポリマーの水性分散液で被膜した放出制御型製剤及びその方法
PL2358360T3 (pl) * 2008-11-18 2017-02-28 Ucb Biopharma Sprl Preparaty o przedłużonym uwalnianiu zawierające pochodną 2-okso-1-pirolidyny
BRPI1001091A2 (pt) * 2009-04-22 2011-03-22 Dr Suwelack Skin & Health Care Ag artigo moldado revestido secado por congelamento
RU2563623C2 (ru) 2009-12-02 2015-09-20 Апталис Фарма Лимитед Микрокапсулы фексофенадина и содержащие их композиции
CN103228676B (zh) * 2010-12-03 2016-10-19 日本曹达株式会社 羟烷基纤维素
ES2973539T3 (es) 2011-03-23 2024-06-20 Ironshore Pharmaceuticals & Dev Inc Métodos y composiciones para el tratamiento del trastorno por déficit de atención
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US8927010B2 (en) 2011-03-23 2015-01-06 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US8916588B2 (en) 2011-03-23 2014-12-23 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
JP5146859B2 (ja) * 2011-07-11 2013-02-20 ユーロ−セルティーク エス．エイ． アクリル系ポリマーの水性分散液で被膜した放出制御型製剤及びその方法
CA2936746C (en) 2014-10-31 2017-06-27 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
AR121619A1 (es) * 2020-03-25 2022-06-22 Inibsa Ginecologia S A Una forma de dosificación oral de múltiples unidades de liberación modificada de succinato de doxilamina y clorhidrato de piridoxina y un procedimiento para su preparación

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5944311A (ja) * 1982-09-07 1984-03-12 Santen Pharmaceut Co Ltd 徐放性顆粒およびその製造法
IE56999B1 (en) * 1983-12-22 1992-03-11 Elan Corp Plc Pharmaceutical formulation
US5002776A (en) * 1983-12-22 1991-03-26 Elan Corporation, Plc Controlled absorption diltiazem formulations
US4559225A (en) * 1984-02-16 1985-12-17 Fourman Robert G Sunscreen composition
JPH0621066B2 (ja) * 1984-03-14 1994-03-23 杏林製薬株式会社 ３―イソブチリル―２―イソプロピルピラゾロ〔１，５―ａ〕ピリジンの徐放性医薬品組成物
GB8518301D0 (en) * 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
GB8707416D0 (en) * 1987-03-27 1987-04-29 Wellcome Found Pharmaceutical formulations
IL88083A (en) * 1987-11-06 1992-11-15 Tanabe Seiyaku Co Controlled release pharmaceutical dosage form and its preparation
DE59000232D1 (de) * 1989-02-11 1992-09-10 Bayer Ag Arzneimittel mit kontrollierter wirkstoffabgabe.
US4983401A (en) * 1989-05-22 1991-01-08 Kinaform Technology, Inc. Sustained release pharmaceutical preparations having pH controlled membrane coatings
US5013557A (en) * 1989-10-03 1991-05-07 Warner-Lambert Company Taste masking compositions comprising spray dried microcapsules containing sucralfate and methods for preparing same
JPH0674206B2 (ja) * 1989-12-28 1994-09-21 田辺製薬株式会社 放出制御型製剤およびその製法

Also Published As

Publication number Publication date
ES2055962T3 (es) 1994-09-01
HU214590B (hu) 1998-04-28
CN1040061C (zh) 1998-10-07
JPH04235123A (ja) 1992-08-24
GR3024471T3 (en) 1997-11-28
CN1058533A (zh) 1992-02-12
CA2045358A1 (en) 1991-12-29
EP0463877B2 (en) 1997-07-02
FI912952A0 (fi) 1991-06-18
HUT59321A (en) 1992-05-28
IL98611A0 (en) 1992-07-15
FI103476B (fi) 1999-07-15
FI103476B1 (fi) 1999-07-15
FI912952L (fi) 1991-12-29
CA2045358C (en) 1998-04-28
EP0463877B1 (en) 1994-06-01
HU912170D0 (en) 1991-12-30
HK33895A (en) 1995-03-17
IE64629B1 (en) 1995-08-23
IE912166A1 (en) 1992-01-01
JP2558396B2 (ja) 1996-11-27
SG4995G (en) 1995-06-16
AU634400B2 (en) 1993-02-18
DE69102211D1 (de) 1994-07-07
US5137733A (en) 1992-08-11
DE69102211T3 (de) 1997-08-28
KR920000313A (ko) 1992-01-29
IL98611A (en) 1998-10-30
DE69102211T2 (de) 1994-09-15
KR0133511B1 (ko) 1998-04-23
ATE106241T1 (de) 1994-06-15
EP0463877A1 (en) 1992-01-02
DK0463877T3 (da) 1994-06-27
AU7924391A (en) 1992-01-02

Similar Documents

Publication Publication Date Title
ES2055962T3 (es) Preparado farmaceutico de liberacion controlada.
ES2138584T3 (es) Sistema de suministro de farmacos que implica la reaccion entre una proteina o un polipeptido y un polimero biodegradable hidrofobo.
ES2060074T3 (es) Una preparacion farmaceutica de liberacion controlada y un metodo para su obtencion.
ES2031302T3 (es) Procedimiento para la obtencion de un sistema osmotico oral con efecto de adherencia mejorado de la membrana sobre el nucleo.
SE8703034L (sv) Oralt terapeutiskt system med systemisk verkan
ES2064564T3 (es) Sistema de liberacion pulsatil de dosis unitaria diaria de minociclina.
ATE99927T1 (de) Pharmazeutische formulierungen.
ES2087281T3 (es) Sistema de produccion de fluidos de dialisis con pildora de dialisis.
ATE53176T1 (de) Pharmazeutische zusammensetzung mit verzoegerter abgabe.
ATE173159T1 (de) Auf hydroxyethylzellulose basierende oralen arzneidosisformen mit verzoegerter wirkstoffabgabe
IT1201136B (it) Compressa per uso farmaceutico atta al rilascio in tempi successivi di sostanze attive
AR065072A2 (es) Una formulacion medicamentosa de pellet de difusion controlada que tiene liberacion controlada de un compuesto activo
ES2059844T3 (es) Pelicula aplicable a la mucosa oral y preparacion de farmaco que la comprende.
ES2051881T3 (es) Procedimiento de preparacion de un formulacion farmaceutica de liberacion prolongada.
ES2050363T3 (es) Sistema para la liberacion intraoral de medicamento.
EP0616802A4 (en) Oral preparation for release in lower digestive tracts.
AR030099A1 (es) Composicion de eletriptan en forma de particulas
DK0994887T3 (da) Modificerede glycosider, præparater omfattet deraf og fremgangsmåder til anvendelse deraf
AR038373A1 (es) Sistema de suministro osmotico
PE20010568A1 (es) Formulaciones orales de liberacion controlada
ES2093812T3 (es) Un bencenodimetanol adecuado para micronizacion.
ES2086541T3 (es) Activacion de hidrolasa de polisacaridos.
ES2040891T3 (es) Nuevo sistema plastificante hidrofilo y goma de mascar que contiene el mismo.
MX9301189A (es) Forma de administracion farmaceutica, solida, finamente dividida, para administracion oral, disuelta o suspendida en un liquido farmaceuticamente aceptable y procedimiento para su preparacion.
ES2164849T3 (es) Soluciones acuosas con sabor enmascarado que contienen ibuprofeno y mentol.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 463877

Country of ref document: ES